ABSCI CORPORATION
| Revenue | $3.9M |
|---|---|
| Operating income | $-79.1M |
| Net income | $-74.1M |
| Free cash flow | $-55.8M |
| Operating margin | -2044.8% |
| Net margin | -1915.8% |
| Return on equity | -36.8% |
| Period | 2024 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
ABSCI remains a high-risk, catalyst-driven biotech rather than a buy on fundamentals:
Q2 revenue fell to $0.3 million, net loss widened to $33.2 million, and the company remains dependent on ABS-201 clinical validation. The $201.1 million cash balance, including $93.6 million of financing proceeds and a $40 million Eli Lilly investment, funds operations into 2H 2028 and removes near-term financing risk; however, the core bull case still rests on unproven hair-growth efficacy, durability, and receptor-occupancy assumptions. Interim 13-week data are expected in late 2026, with 26-week data in early 2027, making those readouts the key investment test.
- Abs 201
- Pattern Hair Loss
- Endometriosis
- Eli Lilly Investment
- Headline Trial
- Atlas Platform
Near term
The late-2026 13-week ABS-201 pattern-hair-loss readout should include target-area hair count, hair width, darkness, and updated safety/tolerability; management framed this as a directional signal rather than a definitive efficacy result.
Management said the multiple-ascending-dose portion of HEADLINE is enrolling on plan and indicated that interim hair-loss data are expected before initiation of the endometriosis study, anticipated in Q4 2026.
The financing materially reduces dilution and liquidity pressure in the near term, with $201.1 million of cash and marketable securities at quarter-end and a projected runway into the second half of 2028.
The $40 million Eli Lilly investment and clinical-development collaboration may improve credibility, but Lilly receives no rights to ABS-201 and the program remains internally funded and developed.
Longer term
ABS-201 could become commercially differentiated if its estimated half-life of at least 65 days translates into 2-3 doses over six months while maintaining more than 90% receptor occupancy and durable hair regrowth.
The endometriosis opportunity is strategically important, but the stated greater-than-$4 billion peak-sales potential is an unvalidated market estimate that still depends on Phase II proof of concept, safety, regulatory success, and competitive positioning.
Atlas and Origin could improve the economics of internal pipeline creation; management cited prior programs reaching IND-enabling studies in under 2.5 years and under $15 million, plus a claimed 1,000-fold reduction in library size for lead identification. These are platform-efficiency claims, not yet demonstrated clinical productivity.
Competitive risk remains material: management argued that HMI-115 failed to sustain more than 90% receptor occupancy, but this is management's interpretation of a competitor's data and does not establish that ABS-201 will deliver superior clinical outcomes.
The company intends to commercialize ABS-201 and future programs itself where capital economics permit, creating greater upside but also exposing investors to substantial future clinical, regulatory, commercial, and execution requirements.
Red flags
Management did not provide a quantitative target for the terminal-to-vellus ratio and acknowledged it was not aware of comparable ratio data, leaving an important efficacy benchmark undefined.
Durability—the central commercial differentiator for infrequent dosing—will not be answered by either the 13-week or 26-week readout. Management said only that the post-trial safety follow-up may provide an initial indication, with the ultimate durability plan still unresolved.
The 30-35 hairs per square centimeter target and $25 billion U.S. market estimate are based on consumer research, KOL feedback, and hypothetical product profiles rather than clinical results.
The interim Phase I data remain blinded aggregate safety and PK observations. No clinical hair-growth efficacy has yet been disclosed, and the claimed greater-than-90% receptor occupancy is based on modeling rather than demonstrated patient outcomes.
Management's explanation for HMI-115's apparent shortcomings and its claim that sustained receptor occupancy will produce robust efficacy remain mechanistic hypotheses; analysts' questions exposed the lack of a validated clinical benchmark.
Revenue was only $0.3 million and fluctuates with partner milestones, so the business currently lacks a recurring commercial revenue base.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-03-24
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 654.3%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -4113.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -3318.8%
- Cash Runway Low — Cash runway ~0.2 years
- Accumulated Deficit High — Accumulated deficit / equity 330%
- Rd Intensity High — R&D/Revenue 2907.8%
Upcoming earnings
Earnings transcripts
Press & signals
- GlobeNewswire
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- Satelight
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-
- Satelight
Absci Reports Business Updates and Second Quarter 2026 Financial and